Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme Therapeutics (HALO) reaffirmed its projection of zero to minimal royalty revenue impact from Medicare drug price negotiations through at least 2035.
The company bases its outlook on its analysis of the final rule for the Medicare Drug Price Negotiation Program, issued by CMS on November 5, 2026, and the statutory framework under the One Big Beautiful Bill Act. Halozyme also projects no impact on its ability to execute new ENHANZE partnership agreements. Its outlook draws on final-rule statements affirming that orphan drug protections remain applicable and addressing how biosimilar entry affects program eligibility.
Halozyme Therapeutics (HALO) announced FDA accelerated approval of Johnson & Johnson's RYBREVANT FASPRO for a defined group of head and neck cancer patients. The treatment combines amivantamab and hyaluronidase-lpuj with Halozyme's ENHANZE technology. Approval covers use as a single agent in adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody, a type of immunotherapy.
The indication excludes HPV-associated oropharyngeal squamous cell carcinoma, a cancer of the middle part of the throat. RYBREVANT FASPRO targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET). Johnson & Johnson issued its approval announcement on November 5, 2026.
Halozyme Therapeutics (HALO) reported third-quarter 2026 revenue of $493.0 million and raised its full-year financial guidance after higher royalty revenue. Revenue rose 39% year over year, while royalties increased 44% to $341.0 million. Net income reached $247.0 million versus $175.2 million, and GAAP diluted earnings per share rose to $2.01 from $1.43.
Halozyme now expects 2026 revenue of $1.860–$1.925 billion, adjusted EBITDA of $1.240–$1.290 billion and non-GAAP diluted earnings per share of $8.75–$9.05. It completed $1.5 billion in convertible-note financing and $400 million in share repurchases this year. Collaboration agreements expanded with argenx, Incyte and Janssen, while three ENHANZE programs entered Phase 1 clinical development. Cash, cash equivalents, restricted cash and marketable securities totaled $1.08 billion at September 30, 2026, versus $145.4 million at December 31, 2025.
Halozyme Therapeutics (Nasdaq: HALO) will release its third quarter 2026 financial and operating results on November 5, 2026, after trading closes.
The company will host a conference call that day at 1:30 p.m. PT/4:30 p.m. ET. A live webcast and replay will be available through the Investors section of its corporate website.
Halozyme Therapeutics (HALO) obtained a Dutch court injunction restricting Merck's Keytruda SC activities across eight European markets following a patent infringement finding.
The ruling covers patent EP 2,797,622 and restricts MSD BV's manufacturing and distribution activities. The court rejected Merck's invalidity arguments. Intravenous Keytruda remains available. Halozyme says MDASE patent enforcement will not affect ENHANZE licensees' usage rights or license fees.
Halozyme Therapeutics (HALO) expanded its global collaboration and license agreement with argenx to include two additional exclusive targets using ENHANZE.
The expansion increases argenx's exclusive access from six to eight targets to support development and commercialization of subcutaneous formulations, delivered under the skin. Halozyme is eligible for payments upon achievement of agreed milestones and will receive royalties on net sales of products using ENHANZE. The collaboration has previously supported development of VYVGART Hytrulo.
Halozyme Therapeutics (HALO) appointed James “Jim” Daly to its Board of Directors, bringing a former director back to the board. Daly has more than three decades of commercial leadership experience in the biopharmaceutical industry.
He served as Executive Vice President and Chief Commercial Officer of Incyte from 2012 to 2015, following a decade at Amgen and more than 16 years at Glaxo Wellcome/GlaxoSmithKline. He currently serves on the boards of Acadia Pharmaceuticals, Madrigal Pharmaceuticals and Cytokinetics.
Halozyme Therapeutics (HALO) priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 on September 17, 2026.
The notes, offered to qualified institutional buyers under Rule 144A, carry semi-annual interest and mature on October 1, 2033. They are initially convertible at 7.1509 shares per $1,000, implying a conversion price of about $139.84, a 27.5% premium to the $109.68 closing share price. Halozyme granted a 13‑day option for up to an additional $200 million of notes and expects net proceeds of about $1.275 billion (or $1.471 billion if the option is fully exercised).
The company plans to spend approximately $162.5 million on capped call transactions with a cap price of about $208.39 and to use part of the proceeds to repurchase outstanding 2027 and 2028 convertible notes, with the remainder for general corporate purposes and potential future note repurchases.
Halozyme Therapeutics (HALO) plans to offer $1.05 billion of convertible senior notes due 2033 in a private Rule 144A placement to qualified institutional buyers.
The company expects to grant initial purchasers a 13-day option for up to an additional $150 million of notes. The unsecured notes will pay semi-annual interest, mature on October 1, 2033, and be convertible under specified conditions before April 1, 2033, and at any time thereafter until shortly before maturity. Halozyme plans to settle conversions in cash and, at its election, common stock, and intends to enter capped call transactions to reduce potential dilution. Net proceeds will fund the capped calls, repurchases of existing 2027 and 2028 convertible notes, and general corporate purposes.
Halozyme (HALO) will participate in three upcoming investor conferences in September 2026, featuring fireside chats and 1x1 investor meetings with its President and CEO and CFO.
Events include the Wells Fargo 21st Annual Healthcare Conference on September 9 at 12:45pm PT, the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 4:45am PT, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 7:00am PT. A live audio webcast and 90-day replays will be available in the Investor Relations section of Halozyme’s website.